Vanguard Global Advisers’s Starling Oncology STLN Stock Holding History
Bought
Maintained
Sold
Other funds holding STLN
JAIC
Vanguard Global Advisers's STLN Position: Q3 2026 in Review
Vanguard Global Advisers increased its Starling Oncology (STLN) stake by 119% in Q3 2026, buying an estimated $205K and bringing the position to 63,240 shares worth $400K. The position accounts for ﹤0.01% of the portfolio, ranked #2192.
Vanguard Global Advisers first reported a position in STLN in Q1 2026 and has held it in 3 quarters since. 130 funds tracked by Wall St. Rank hold STLN as of Q3 2026.
- Vanguard Global Advisers held 63,240 shares of Starling Oncology worth $400K as of Q3 2026.
- Vanguard Global Advisers bought 34,366 Starling Oncology shares in Q3 2026, an estimated $205K.
- Starling Oncology made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2192 holding.
- Vanguard Global Advisers first reported a position in Starling Oncology in Q1 2026 and has held it in 3 quarters since.
- 130 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.